Manufacturing and life sciences investments, particularly Eli Lilly’s $6.5M monster pharmaceutical production facility, provided the biggest reasons for Houston’s commercial real estate industry to be optimistic this year.
Professionals in the office, retail and multifamily asset classes had to look a little harder for data points to energize their entry into 2026, though limited construction pipelines and solid performance at the top end of the market bolstered rental rates and occupancies.  
Life Sciences